All In Biotech

Free tool

FAERS Monitor: Taltz

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125521 or its brand name (Taltz, Ixekizumab). Reports on generic versions are filed under their own applications.

Reports

37,285

Serious

8,108

22% of reports

Hospitalization

3,067

Death reported

561

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • injection site pain3,931
  • psoriasis3,296
  • drug ineffective3,287
  • injection site erythema2,214
  • injection site reaction1,798
  • injection site swelling1,659
  • incorrect dose administered1,199
  • product dose omission issue962
  • pain950
  • covid-19923
  • arthralgia906
  • therapy interrupted845
  • diarrhoea840
  • rash839
  • psoriatic arthropathy821

Reports by year received

View as table
YearReports
2016405
20172,073
20183,763
20194,770
20203,527
20214,001
20225,000
20234,508
20244,451
20253,435
20261,352

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,016,874 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
injection site reactionSignal1,79815.114.423,131
psoriasisSignal3,29614.614.140,874
injection site swellingSignal1,65912.511.917,163
psoriatic arthropathySignal82111.610.97,816
injection site erythemaSignal2,21410.29.818,214
injection site painSignal3,9317.37.121,444
therapy interruptedSignal8456.76.34,088
covid-19Signal9233.02.81,215
incorrect dose administeredSignal1,1993.02.81,577
product dose omission issue9621.81.7378
drug ineffective3,2871.41.4413
arthralgia9061.21.239
rash8391.11.06
pain9500.90.818
diarrhoea8400.70.783

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.